#USA #New York #Gross Law Firm #VTGN #Vistagen Therapeutics

Investors in Vistagen Therapeutics: Important Notice to Act

Investors who have purchased shares of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) are urged to contact The Gross Law Firm before March 16, 2026, to discuss their rights regarding potential recovery from recent financial losses. This notice is crucial for shareholders who acquired their shares during the specified class period, which spans from April 1, 2024, to December 16, 2025.

Background on the Case

Allegations have emerged claiming that Vistagen provided misleading statements to investors while withholding significant adverse information about their Phase 3 clinical trial, PALISADE-3, concerning fasedienol, a drug developed for treating social anxiety disorder. The research revealed disappointing results, sparking confusion and distrust among investors. On December 17, 2025, the company communicated that the trial failed to meet its primary endpoint, revealing no significant difference between the treatment and placebo groups. Consequently, the share price plummeted from $4.36 on December 16, 2025, to $0.86 a day later, marking an alarming drop of over 80%.

What Investors Should Do

Shareholders have until March 16, 2026, to register and potentially pursue lead plaintiff status in a class action lawsuit. This is vital because participating in the case does not necessitate being the lead plaintiff. Those who register will benefit from a portfolio monitoring solution that provides ongoing updates about the case's progression.

The Gross Law Firm, recognized nationally for representing investors, emphasizes the importance of protecting the rights of those impacted by business misconduct. Their objective is to hold companies accountable for misleading information that results in financial damage to shareholders.

As part of their engagement process, interested investors can complete a submission form via The Gross Law Firm’s website to register their interest in the ongoing case. The firm affirms that there are no costs or obligations involved in participating in this initiative.

Next Steps and Support

If you are an eligible shareholder of VTGN, it is crucial to take action promptly to safeguard your financial interests. The necessity for swift action derives from the looming deadline, which is fast approaching. By engaging with The Gross Law Firm, you can ensure that your rights as a shareholder are advocated for effectively.

For inquiries or further assistance, The Gross Law Firm is reachable at:

• - Email: [email protected]
• - Phone: (646) 453-8903
• - Office Address: 15 West 38th Street, 12th floor, New York, NY 10018

Investors are encouraged not to delay in considering this opportunity to assert their rights in light of significant financial obstacles posed by misleading corporate conduct. Timely registration is key to benefitting from potential recovery as stipulated in the legal proceedings against Vistagen.

In summary, shareholders of Vistagen Therapeutics, Inc. have a critical window until March 16, 2026, to join a class action lawsuit. Taking proactive steps can lead to just recourse against the misrepresentation and opacity that have impacted their investments.